EP3793562A4 - METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE - Google Patents

METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE Download PDF

Info

Publication number
EP3793562A4
EP3793562A4 EP19822319.0A EP19822319A EP3793562A4 EP 3793562 A4 EP3793562 A4 EP 3793562A4 EP 19822319 A EP19822319 A EP 19822319A EP 3793562 A4 EP3793562 A4 EP 3793562A4
Authority
EP
European Patent Office
Prior art keywords
inhibition
compositions
methods
dihydroorotate dehydrogenase
dihydroorotate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP19822319.0A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP3793562C0 (en
EP3793562A1 (en
EP3793562B1 (en
Inventor
John C. Byrd
Thomas E. Goodwin
Ola ELGAMAL
Erin HERTLEIN
Mouad ABDULRAHIM
Chad E. Bennett
Sandip Madhukar VIBHUTE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ohio State Innovation Foundation
Hendrix College
Original Assignee
Ohio State Innovation Foundation
Hendrix College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ohio State Innovation Foundation, Hendrix College filed Critical Ohio State Innovation Foundation
Priority to EP24181542.2A priority Critical patent/EP4438042A2/en
Publication of EP3793562A1 publication Critical patent/EP3793562A1/en
Publication of EP3793562A4 publication Critical patent/EP3793562A4/en
Application granted granted Critical
Publication of EP3793562C0 publication Critical patent/EP3793562C0/en
Publication of EP3793562B1 publication Critical patent/EP3793562B1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
    • C07D215/52—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4 with aryl radicals attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
EP19822319.0A 2018-06-22 2019-06-22 Methods and compositions for inhibition of dihydroorotate dehydrogenase Active EP3793562B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP24181542.2A EP4438042A2 (en) 2018-06-22 2019-06-22 Methods and compositions for inhibition of dihydroorotate dehydrogenase

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862688612P 2018-06-22 2018-06-22
PCT/US2019/038622 WO2019246603A1 (en) 2018-06-22 2019-06-22 Methods and compositions for inhibition of dihydroorotate dehydrogenase

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP24181542.2A Division EP4438042A2 (en) 2018-06-22 2019-06-22 Methods and compositions for inhibition of dihydroorotate dehydrogenase

Publications (4)

Publication Number Publication Date
EP3793562A1 EP3793562A1 (en) 2021-03-24
EP3793562A4 true EP3793562A4 (en) 2021-07-07
EP3793562C0 EP3793562C0 (en) 2024-06-19
EP3793562B1 EP3793562B1 (en) 2024-06-19

Family

ID=68984309

Family Applications (2)

Application Number Title Priority Date Filing Date
EP24181542.2A Pending EP4438042A2 (en) 2018-06-22 2019-06-22 Methods and compositions for inhibition of dihydroorotate dehydrogenase
EP19822319.0A Active EP3793562B1 (en) 2018-06-22 2019-06-22 Methods and compositions for inhibition of dihydroorotate dehydrogenase

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP24181542.2A Pending EP4438042A2 (en) 2018-06-22 2019-06-22 Methods and compositions for inhibition of dihydroorotate dehydrogenase

Country Status (13)

Country Link
US (3) US11312686B2 (ja)
EP (2) EP4438042A2 (ja)
JP (1) JP7373170B2 (ja)
KR (1) KR20210048483A (ja)
CN (1) CN112672744B (ja)
AU (2) AU2019288813B2 (ja)
BR (1) BR112020026308A2 (ja)
CA (1) CA3103557A1 (ja)
IL (1) IL279586B (ja)
MX (1) MX2021000143A (ja)
SG (1) SG11202012029PA (ja)
WO (1) WO2019246603A1 (ja)
ZA (1) ZA202007620B (ja)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3094324A1 (en) 2018-03-26 2019-10-03 Clear Creek Bio, Inc. Compositions and methods for inhibiting dihydroorotate dehydrogenase
CA3165512A1 (en) * 2019-12-26 2021-07-01 Ohio State Innovation Foundation Methods and compositions for inhibition of dihydroorotate dehydrogenase
US20230303710A1 (en) * 2019-12-26 2023-09-28 Ohio State Innovation Foundation Methods and compositions for inhibition of dihydroorotate dehydrogenase in combination with an anti-cd38 therapeutic agent
US20210300873A1 (en) 2020-03-20 2021-09-30 Clear Creek Bio, Inc. Stable polymorphic compositions of brequinar sodium and methods of use and manufacture thereof
JP2023518419A (ja) * 2020-03-20 2023-05-01 クリア クリーク バイオ， インコーポレイテッド ブレキナルナトリウムの安定した多形性組成物ならびにその使用および製造方法
EP4436579A1 (en) * 2021-11-22 2024-10-02 Ohio State Innovation Foundation Methods and compositions for targeting alternative metabolism along with flt3 inhibitor-mediated antileukemic actions
CN115532290B (zh) * 2022-10-13 2024-04-30 浙江昌海制药有限公司 一种特定晶面选择性氢化催化剂及其制备方法和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997042953A1 (en) * 1996-05-10 1997-11-20 Novartis Ag Use of brequinar and derivatives in chronic rejection of allografts and xenotransplantation
WO2014117090A1 (en) * 2013-01-28 2014-07-31 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2888346A (en) * 1955-08-22 1959-05-26 Gen Aniline & Film Corp Ultra-violet absorbing compounds
US6841561B1 (en) 1999-10-01 2005-01-11 Institute Of Molecular And Cell Biology Dihydroorotate dehydrogenase inhibitors for the treatment of viral-mediated diseases
EP1237546A2 (en) 1999-10-01 2002-09-11 Institute of Molecular and Cell Biology Dihydroorotate dehydrogenase inhibitors for the treatment of viral-mediated diseases
WO2003097164A1 (en) 2002-05-17 2003-11-27 Aventis Pharma S.A. Use of docetaxel/doxorubicin/cyclophosphamide in adjuvant therapy of breast and ovarian cancer
RS57962B1 (sr) 2013-02-25 2019-01-31 Aurigene Discovery Tech Ltd Derivati trisupstituisanog benzotriazola kao inhibitori dihidroorotat oksigenaze

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997042953A1 (en) * 1996-05-10 1997-11-20 Novartis Ag Use of brequinar and derivatives in chronic rejection of allografts and xenotransplantation
WO2014117090A1 (en) * 2013-01-28 2014-07-31 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MADAK JOSEPH T. ET AL: "Design, Synthesis, and Biological Evaluation of 4-Quinoline Carboxylic Acids as Inhibitors of Dihydroorotate Dehydrogenase", JOURNAL OF MEDICINAL CHEMISTRY, vol. 61, no. 12, 4 May 2018 (2018-05-04), US, pages 5162 - 5186, XP055790577, ISSN: 0022-2623, Retrieved from the Internet <URL:https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.7b01862> DOI: 10.1021/acs.jmedchem.7b01862 *

Also Published As

Publication number Publication date
JP2021530559A (ja) 2021-11-11
US20240294477A1 (en) 2024-09-05
MX2021000143A (es) 2021-08-05
US20210253531A1 (en) 2021-08-19
AU2023233065A1 (en) 2023-10-05
US20220064119A1 (en) 2022-03-03
CA3103557A1 (en) 2019-12-26
EP4438042A2 (en) 2024-10-02
CN112672744A (zh) 2021-04-16
BR112020026308A2 (pt) 2021-03-30
US11999697B2 (en) 2024-06-04
KR20210048483A (ko) 2021-05-03
IL279586B (en) 2021-09-30
AU2019288813B2 (en) 2023-06-29
AU2019288813A1 (en) 2021-01-07
ZA202007620B (en) 2023-02-22
CN112672744B (zh) 2022-10-14
IL279586A (en) 2021-01-31
WO2019246603A1 (en) 2019-12-26
EP3793562C0 (en) 2024-06-19
EP3793562A1 (en) 2021-03-24
US11312686B2 (en) 2022-04-26
JP7373170B2 (ja) 2023-11-02
SG11202012029PA (en) 2021-01-28
EP3793562B1 (en) 2024-06-19

Similar Documents

Publication Publication Date Title
EP3793562A4 (en) METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE
EP4054621A4 (en) COMPOSITIONS AND METHODS FOR REPLACING RNA-ENCODED DNA ALLELES
EP3589291A4 (en) COMPOSITIONS AND METHODS OF INHIBITION OF LINE-SPECIFIC PROTEINS
EP3573623A4 (en) COMPOSITIONS AND METHODS OF INHIBITION OF GENE EXPRESSION OF FACTOR XII
EP3679141A4 (en) METHODS AND COMPOSITIONS FOR INHIBITING LDHA EXPRESSION
EP3856176A4 (en) VAP-1 INHIBITORS
EP4069212A4 (en) HIF-2 ALPHA INHIBITORS
EP3911338A4 (en) COMPOSITIONS AND METHODS FOR INHIBITION OF CELL LINE SPECIFIC ANTIGENS
EP3962479A4 (en) KCNT1 INHIBITORS AND METHODS OF USE
EP3768267A4 (en) KINA INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE
EP3962481A4 (en) KCNT1 INHIBITORS AND METHODS OF USE
EP3983386A4 (en) ACSS2 INHIBITORS AND METHODS OF USE
EP3982949A4 (en) MRSA1 INHIBITORS
EP3856214A4 (en) MICROBIAL COMPOSITIONS AND METHODS OF USE
EP3980011A4 (en) MRSA1 INHIBITORS
EP3768301A4 (en) COMPOSITIONS AND METHODS FOR FAS INHIBITION
EP3829307A4 (en) BISMUTH-THIOL COMPOSITIONS AND METHODS OF USE
EP3986894A4 (en) ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF
EP3856194A4 (en) VAP-1 INHIBITORS
EP3906028A4 (en) KINA INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE
EP3906233A4 (en) KINA INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE
EP3555079A4 (en) INHIBITORS OF MUTANT ISOCITRATEHYDROGENASES AND COMPOSITIONS AND METHODS FOR THEREOF
EP3959197A4 (en) PAPD5 INHIBITORS AND METHODS OF USE THEREOF
EP3934426A4 (en) PRESERVATION COMPOSITIONS AND METHODS OF USE THEREOF
EP3841114A4 (en) METHODS AND COMPOSITIONS FOR RNA EXPRESSION OF MYC INHIBITORS

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20201215

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Ref document number: 602019053953

Country of ref document: DE

Free format text: PREVIOUS MAIN CLASS: A61K0031519000

Ipc: A61K0031573000

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: A61K0031519000

Ipc: A61K0031573000

A4 Supplementary search report drawn up and despatched

Effective date: 20210607

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/573 20060101AFI20210531BHEP

Ipc: A61K 31/519 20060101ALI20210531BHEP

Ipc: A61K 31/506 20060101ALI20210531BHEP

Ipc: A61P 17/06 20060101ALI20210531BHEP

Ipc: A61P 35/00 20060101ALI20210531BHEP

Ipc: A61P 37/06 20060101ALI20210531BHEP

Ipc: A61K 45/06 20060101ALI20210531BHEP

Ipc: C07D 215/12 20060101ALI20210531BHEP

Ipc: A61K 31/47 20060101ALI20210531BHEP

Ipc: A61K 31/436 20060101ALI20210531BHEP

Ipc: A61K 31/451 20060101ALI20210531BHEP

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20230123

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20240112

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20240627

Year of fee payment: 6

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602019053953

Country of ref document: DE

U01 Request for unitary effect filed

Effective date: 20240711

U07 Unitary effect registered

Designated state(s): AT BE BG DE DK EE FI FR IT LT LU LV MT NL PT SE SI

Effective date: 20240722

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240619

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240920